Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy

British Journal of Ophthalmology

Volumn 98, Issue 12, 2014, Pages 1629-1635

  Ritter, Markus ^a   Simader, Christian ^a   Bolz, Matthias ^a   Deák, Gábor G ^a   Mayr Sponer, Ulrike ^a   Sayegh, Ramzi ^c   Kundi, Michael ^b   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Medical University of Vienna and Wiener Werkstaette for Suicide Research   (Austria)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYST; DISEASE MARKER; DOUBLE BLIND PROCEDURE; HUMAN; INTRARETINAL CYST; MAJOR CLINICAL STUDY; MORPHOLOGY; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINAL THICKNESS; SUBRETINAL FLUID; VISUAL ACUITY; VISUAL FIELD; CLINICAL TRIAL; INTRAVITREAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSPECTIVE STUDY; RETINA; RETINA DISEASE; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; CYSTS; DOUBLE-BLIND METHOD; HUMANS; INTRAVITREAL INJECTIONS; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROGNOSIS; PROSPECTIVE STUDIES; RETINA; RETINAL DISEASES; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84911987296     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305186     Document Type: Article

References (24)

1. Ferrara N, Mass RD, Campa C, et al. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007;58:491-504.
2. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
4. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
5. Vertepor fin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-vertepor fin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
6. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Vertepor fin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012;119:992-1000.
7. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfi n plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012;119:1001-10.
8. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
9. Moutray T, Alarbi M, Mahon G, et al. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol 2008;92: 361-4.
10. Keane PA, Liakopoulos S, Chang KT, et al . Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmology 2008;115:2206-14.
11. Golbaz I, Ahlers C, Stock G, et al. Quanti fication of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 2011;52:1599-605.
12. Kiss CG, Geitzenauer W, Simader C, et al. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50:2376-83.
13. Keane PA, Heussen FM, Ouyang Y, et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2012;53: 1152-61.
14. Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;120:1860-70.
15. Rogers AH, Martidis A, Greenberg PB, et al. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2002;134:566-76.
16. Krebs I, Binder S, Stolba U, et al. Optical coherence tomography guided retreatment of photodynamic therapy. Br J Ophthalmol 2005;89:1184-7.
17. Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina 2005;25:691-6.
18. Kiss CG, Simader C, Michels S, et al . Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study. Br J Ophthalmol 2008;92:1620-7.
19. Tozer K, Roller AB, Chong LP, et al. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology 2013;120:2029-34.
20. Ritter M, Elledge J, Simader C, et al. Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres. Br J Ophthalmol 2011;95:381-5.
21. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002;43:830-41.
22. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-9.
23. Simader C, Ritter M, Bolz M., et al Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 2014;121:1237-45.
24. Chhablani J, Kim JS, Freeman WR, et al. Predictors of visual outcome in eyes with choroidal neovascularization secondary to age related macular degeneration treated with intravitreal bevacizumab monotherapy. Int J Ophthalmol 2013;6:62-6.